Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Lilly Closes Its Singapore Drug Discovery Center; Is China Discovery Unit In The Works?

This article was originally published in PharmAsia News

Executive Summary

Eli Lilly announced Oct. 18 that it will shut the doors of its eight-year-old Lilly Singapore Center for Drug Discovery

You may also be interested in...



An Asia Hub: Novartis Plans Biotech Manufacturing Center In Singapore

Novartis plans to build a new center of excellence for biotechnology manufacturing costing more than $500 million, as it looks to leverage Singapore’s skilled labor force and proximity to growth markets like China.

Merck's $800 Million Investment In Singapore Aims To Produce Returns Elsewhere

SINGAPORE - Merck & Co. Inc. has committed to manufacturing and research investments in Singapore totaling more than $800 million to meet the ever increasing demand in nearby emerging markets

Merck's $800 Million Investment In Singapore Aims To Produce Returns Elsewhere

SINGAPORE - Merck & Co. Inc. has committed to manufacturing and research investments in Singapore totaling more than $800 million to meet the ever increasing demand in nearby emerging markets

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip
In Vivo
Scrip
Tags:
Latest Headlines

Executives On The Move: C-Suite Changes At ImmunoGen, Kronos Bio, Verve Therapeutics And More

Promising Early Results For AZ And Daiichi’s Dato-DXd In Breast Cancer – But How Soon Can They File?

BenevolentAI Still Bullish As CEO Shields Steps Down

Glenmark Divests API Company, Setting Out On Distinct Journeys

See All
UsernamePublicRestriction

Register

SC073316

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By